Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC)

被引：0
|
作者：
Abbas, Anser Ali
Davelaar, John
Gai, Jessica
Brown, Zachariah
Levi, Abrahm
Linden, Sheila
Minasyan, Angela
Rodriguez, Christina
Pachter, Jonathan A.
Gong, Jun
Larson, Brent K.
Hendifar, Andrew Eugene
Lo, Simon
Gaddam, Srinivas
Kosari, Kambiz
Nissen, Nicholas
Pandol, Stephen Jacob
Burkhart, Richard
Zheng, Lei
Osipov, Arsen
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA USA
[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Verastem Inc, Needham, MA USA
[5] Samuel Oschin Canc Ctr, Cedars Sinai Med Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4024
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).
    Wei, Alice Chia-chi
    Ou, Fang-Shu
    Shi, Qian
    O'Reilly, Eileen Mary
    Meyerhardt, Jeffrey A.
    Wolff, Robert A.
    Kindler, Hedy L.
    Evans, Douglas B.
    Deshpande, Vikram
    Misdraji, Joseph
    Tamm, Eric P.
    Sahani, Dushyant
    Moore, Malcolm J.
    Newman, Elliot
    Merchant, Nipun B.
    Berlin, Jordan
    Goff, Laura Williams
    Pisters, Peter W. T.
    Posner, Mitchell C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Loss of PTEN expression in tumor microenvironment correlates with aggressive behaviour and detects synergistic roles of tumor and stromal cells in Pancreatic Ductal Adenocarcinoma (PDAC)
    Karamitopoulou, E.
    Zlobec, I.
    Lugli, A.
    Gloor, B.
    Perren, A.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 290 - 291
  • [33] Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
    Coveler, Andrew L.
    Bajor, David Lawrence
    Masood, Ashiq
    Yilmaz, Emrullah
    Shields, Anthony Frank
    Javle, Milind M.
    Paluri, Ravi Kumar
    Vaccaro, Gina M.
    Zalupski, Mark
    Grilley-Olson, Juneko E.
    Kindler, Hedy L.
    Schmitt, Michael W.
    Gutierrez, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Phase II trial of BPM31510-IV plus gemcitabine in advanced pancreatic ductal adenocarcinomas (PDAC)
    Kundranda, Madappa N.
    Propper, David
    Ritch, Paul S.
    Strauss, James
    Hidalgo, Manuel
    Gillmore, Roopinder
    Sarangarajan, Rangaprasad
    Narain, Niven R.
    Kiebish, Michael A.
    Rodrigues, Leonardo O.
    Granger, Elder
    Ramanathan, Ramesh
    Alistar, Angela Tatiana
    Bui, Lynne A.
    Chawla, Sant P.
    Niewiarowska, Anna A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [35] A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
    Lee, Choong-kun
    Hwang, Ho Kyoung
    Jeung, Hei-Cheul
    Chon, Hongjae
    Park, Hyung Soon
    Kim, Min Hwan
    Kim, Sung Hyun
    Park, Mi-Suk
    Kang, Chang Moo
    Choi, Hye Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 715 - 715
  • [36] Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: A prospective, multi-institutional, phase II trial
    Mizuma, Masamichi
    Motoi, Fuyuhiko
    Ishida, Kazuyuki
    Fujishima, Fumiyoshi
    Ottomo, Shigeru
    Oikawa, Masaya
    Okada, Takaho
    Shimamura, Hiromune
    Takemura, Shinichi
    Ono, Fuminori
    Akada, Masanori
    Nakagawa, Kei
    Katayose, Yu
    Egawa, Shinichi
    Unno, Michiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [37] Prospective phase II trial of Neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head
    Heinrich, Stefan
    Pestalozzi, Bernhard C.
    Schaefer, Markus
    Weber, Achim
    Bauerfeind, Peter
    Knuth, Alexander
    Clavien, Pierre-Alain
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2526 - 2531
  • [38] Phase I/II trial of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Waypa, Jordan
    Coats, Jessica
    Blaydorn, Lisa
    McGahey, Kayla
    Sangal, Ashish
    Whitehead, Robert P.
    Khemka, Vivek
    CANCER RESEARCH, 2017, 77
  • [39] Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).
    Yoo, Changhoon
    Kim, Kyu-Pyo
    Song, Ki Byung
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Lee, Seung Soo
    Park, Jin-Hong
    Hwang, Dae Wook
    Lee, Jae Hoon
    Shin, Sang Hyun
    Shin, Eunseon
    Ryoo, Baek-Yeol
    Kim, Song Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [40] Randomized phase 2 trial of peri-or post-operative chemotherapy in resectable pancreatic adenocarcinoma
    Reni, M.
    Zanon, S.
    Balzano, G.
    Castoldi, R.
    Zerbi, A.
    Tronconi, M. C.
    Pinelli, D.
    Mosconi, S.
    Doglioni, C.
    Galli, F.
    Falconi, M.
    Gianni, L.
    ANNALS OF ONCOLOGY, 2017, 28
12345